Tags

Type your tag names separated by a space and hit enter

Steady-state haemoglobin level in sickle cell anaemia increases with an increase in erythrocyte membrane n-3 fatty acids.

Abstract

The aim of the study was to investigate, whether (a) patients with homozygous sickle cell disease (SCD, HbSS) have abnormal blood fatty acids; (b) the abnormality, if it exists, affects all the plasma and erythrocyte lipids or it is restricted to a particular lipid moiety; (c) there is an association between levels of membrane n-3 or n-6 long-chain polyunsaturated fatty acids (LCPUFA) and the degree of anaemia. Fatty acids of erythrocyte choline (CPG), serine (SPG) and ethanolamine (EPG) phosphoglycerides and sphingomyelin (SPM); and plasma CPG, triglycerides and cholesterol esters of 43 steady-state HbSS patients and 43 ethnically matched, healthy, HbAA controls were analysed. The levels of the n-6 LCPUFA, arachidonic (AA), adrenic and docosapentaenoic acids in erythrocyte CPG (P<0.001) and EPG (P<0.01) were higher in the patients compared with the controls. In contrast, the proportions of eicosapentaenoic acid (EPA) in CPG and EPG (P<0.001) and docosahexaenoic acid (DHA) and total n-3 metabolites in CPG (P<0.001) were lower in the patients. The steady-state haemoglobin level of the patients correlated with erythrocyte DHA (r=0.55, P<0.01), EPA (r=0.38, P<0.05) and total n-3 metabolites (r=0.51, P<0.001) in CPG. Also, it correlated with erythrocyte EPA (r=0.64, P<0.01) and total n-3 metabolites (r=0.42, P<0.01) in EPG. The study revealed an imbalance between n-3 and n-6 LCPUFA in erythrocyte and plasma lipid moieties of the HbSS group. Furthermore, it suggested that correction of the imbalance by supplementation with EPA and DHA could ameliorate anaemia in the patients. This observation is consistent with the results of pilot studies, which demonstrated that treatment with n-3 fatty acids confers clinical benefit to sickle cell patients.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Institute of Brain Chemistry and Human Nutrition, London Metropolitan University, 166-220 Holloway Road, London N7 8DB, UK. hor016@unl.ac.uk

    , , , ,

    Source

    MeSH

    Anemia
    Anemia, Sickle Cell
    Arachidonic Acid
    Case-Control Studies
    Erythrocyte Membrane
    Fatty Acids, Omega-3
    Fatty Acids, Omega-6
    Hemoglobins
    Humans
    Membrane Lipids
    Phospholipids

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    15876528

    Citation

    Ren, Hongmei, et al. "Steady-state Haemoglobin Level in Sickle Cell Anaemia Increases With an Increase in Erythrocyte Membrane N-3 Fatty Acids." Prostaglandins, Leukotrienes, and Essential Fatty Acids, vol. 72, no. 6, 2005, pp. 415-21.
    Ren H, Obike I, Okpala I, et al. Steady-state haemoglobin level in sickle cell anaemia increases with an increase in erythrocyte membrane n-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2005;72(6):415-21.
    Ren, H., Obike, I., Okpala, I., Ghebremeskel, K., Ugochukwu, C., & Crawford, M. (2005). Steady-state haemoglobin level in sickle cell anaemia increases with an increase in erythrocyte membrane n-3 fatty acids. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 72(6), pp. 415-21.
    Ren H, et al. Steady-state Haemoglobin Level in Sickle Cell Anaemia Increases With an Increase in Erythrocyte Membrane N-3 Fatty Acids. Prostaglandins Leukot Essent Fatty Acids. 2005;72(6):415-21. PubMed PMID: 15876528.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Steady-state haemoglobin level in sickle cell anaemia increases with an increase in erythrocyte membrane n-3 fatty acids. AU - Ren,Hongmei, AU - Obike,Ibegbulam, AU - Okpala,Iheanyi, AU - Ghebremeskel,Kebreab, AU - Ugochukwu,Cynthia, AU - Crawford,Michael, PY - 2004/11/19/received PY - 2005/02/15/revised PY - 2005/03/21/accepted PY - 2005/5/7/pubmed PY - 2005/10/19/medline PY - 2005/5/7/entrez SP - 415 EP - 21 JF - Prostaglandins, leukotrienes, and essential fatty acids JO - Prostaglandins Leukot. Essent. Fatty Acids VL - 72 IS - 6 N2 - The aim of the study was to investigate, whether (a) patients with homozygous sickle cell disease (SCD, HbSS) have abnormal blood fatty acids; (b) the abnormality, if it exists, affects all the plasma and erythrocyte lipids or it is restricted to a particular lipid moiety; (c) there is an association between levels of membrane n-3 or n-6 long-chain polyunsaturated fatty acids (LCPUFA) and the degree of anaemia. Fatty acids of erythrocyte choline (CPG), serine (SPG) and ethanolamine (EPG) phosphoglycerides and sphingomyelin (SPM); and plasma CPG, triglycerides and cholesterol esters of 43 steady-state HbSS patients and 43 ethnically matched, healthy, HbAA controls were analysed. The levels of the n-6 LCPUFA, arachidonic (AA), adrenic and docosapentaenoic acids in erythrocyte CPG (P<0.001) and EPG (P<0.01) were higher in the patients compared with the controls. In contrast, the proportions of eicosapentaenoic acid (EPA) in CPG and EPG (P<0.001) and docosahexaenoic acid (DHA) and total n-3 metabolites in CPG (P<0.001) were lower in the patients. The steady-state haemoglobin level of the patients correlated with erythrocyte DHA (r=0.55, P<0.01), EPA (r=0.38, P<0.05) and total n-3 metabolites (r=0.51, P<0.001) in CPG. Also, it correlated with erythrocyte EPA (r=0.64, P<0.01) and total n-3 metabolites (r=0.42, P<0.01) in EPG. The study revealed an imbalance between n-3 and n-6 LCPUFA in erythrocyte and plasma lipid moieties of the HbSS group. Furthermore, it suggested that correction of the imbalance by supplementation with EPA and DHA could ameliorate anaemia in the patients. This observation is consistent with the results of pilot studies, which demonstrated that treatment with n-3 fatty acids confers clinical benefit to sickle cell patients. SN - 0952-3278 UR - https://www.unboundmedicine.com/medline/citation/15876528/Steady_state_haemoglobin_level_in_sickle_cell_anaemia_increases_with_an_increase_in_erythrocyte_membrane_n_3_fatty_acids_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0952-3278(05)00042-6 DB - PRIME DP - Unbound Medicine ER -